معرفی
Cary P. Gross, MD is a Professor of Medicine and Epidemiology at Yale School of Medicine, where he founded and directs the COPPER Center (Cancer Outcomes, Public Policy and Effectiveness Research). He also serves as Director of the National Clinician Scholars Program and holds secondary appointments in Chronic Disease Epidemiology. His research focuses on improving cancer care equity through real-world data analysis, comparative effectiveness studies, and health policy evaluation.
- Education: MD from New York University School of Medicine, former Robert Wood Johnson Clinical Scholar
- Research Areas: Geriatric oncology, genomic profiling in cancer, environmental health interactions, health disparities
- Key Collaborators: James B. Yu (78 co-pubs), Michaela Dinan (28 co-pubs), Xiaomei Ma (37 co-pubs)
Recent research trends show his work spans 2025 publications on breast cancer outcomes with antibody-drug conjugates (40532362), structural racism in lung cancer care (DOI:10.1200), and environmental factors influencing cardiovascular outcomes (DOI:10.1161). His team employs advanced biostatistical methods using NCI and American Cancer Society funding.
Scientific Honors include election to Association of American Physicians (2022), Yale Cancer Center Mentorship Excellence (2021), and membership in ASCO and American Society for Clinical Investigation. Current grants address social contagion in cancer technology adoption (NCI Provocative Questions) and breast density legislation impacts.
Clinical mentorship extends through the National Clinician Scholars Program and COPPER Center training initiatives. His team uses large datasets (SEER-Medicare, administrative claims) and prospective studies like the Cancer in Aging Research Group (CARG) cohort to evaluate comorbidity impacts in elderly cancer patients.
Lab & Collaborations: The COPPER Center unites Yale Medicine, Public Health, and Nursing faculty across oncology, geriatrics, and health policy. Current projects examine genomic testing turnaround times (BPI25-017), social risks in clinical settings, and policy impacts on screening disparities.